Abstract
The phase 3 REGAIN study (NCT01997229) and its open-label extension (OLE; NCT02301624) evaluated eculizumab’s efficacy and safety in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (gMG). Although not approved for MG, rituximab has been used in such patients. The aim of this secondary analysis was to assess response to eculizumab in individuals with gMG previously treated with rituximab. Eculizumab is not reimbursed for neurology indications in Italy as of April 2021.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
